Table 3 Univariate and multivariate analysis for PFS
From: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Covariate | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age (≥ 69 years) | 0.7437 (0.4732–1.1688) | 0.2015 | – | – |
Sex | 1.313 (0.8109 -2.126) | 0.268 | – | – |
Weight (≥ 69.5 kg) | 1.1089 (0.6850–1.7950) | 0.6756 | – | – |
Height (> 168 cm) | 1.0502 (0.6274–1.7577) | 0.8530 | – | – |
Liver metastasis | 2.9391 (1.6952–5.0957) | 0.0001 | 3.456 (2.002–5.965) | < 0.0001 |
Lung metastasis | 0.6133 (0.3818–0.9852) | 0.0443 | – | – |
Lymph node metastasis | 0.7610 (0.4697–1.2330) | 0.2697 | – | – |
Only Lymph node metastasis | 0.4324 (0.2567–0.7282) | 0.0017 | – | – |
Brain metastasis | 1.0419 (0.5639–1.9251) | 0.8964 | – | – |
Malignant pleural effusion | 1.0225 (0.4452–2.3485) | 0.9583 | – | – |
Bone metastasis | 1.5459 (0.9538–2.5057) | 0.0786 | – | – |
Adrenal gland metastasis | 1.2286 (0.6145–2.4563) | 0.5623 | – | – |
N. of metastatic sites | 1.1524 (0.8550–1.5533) | 0.3542 | – | – |
ECOG PS | 2.26 (1.602–3.187) | < 0.0001 | 2.260 (1.580–3.233) | < 0.0001 |
Line of treatment | 1.0253 (0.7140–1.4724) | 0.8928 | – | – |
Global | < 0.0001 | |||